Lmr Partners LLP Abb Vie Inc. Transaction History

Lmr Partners LLP

$10.9 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $2.65 Million - $3.3 Million	20,007 New	20,007 $2.7 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $2.91 Million - $3.34 Million	-21,668 Reduced 86.84%	3,283 $441,000
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $3.43 Million - $4.37 Million	24,951 New	24,951 $3.82 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $2.37 Million - $3 Million	-22,097 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $1.19 Million - $1.35 Million	11,200 Added 102.78%	22,097 $2.38 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $888,708 - $990,072	-8,447 Reduced 43.67%	10,897 $1.23 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $1.12 Million - $1.24 Million	10,981 Added 131.3%	19,344 $2.09 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $1.29 Million - $1.74 Million	-16,049 Reduced 65.74%	8,363 $896,000
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $2.1 Million - $2.46 Million	24,412 New	24,412 $2.14 Million
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $1.27 Million - $1.69 Million	-17,254 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $64,306 - $97,496	997 Added 6.13%	17,254 $1.3 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $1.17 Million - $1.47 Million	16,257 New	16,257 $1.44 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $392,715 - $436,576	-4,417 Closed	0 $0
Q2 2018 Aug 03, 2018	SELL	$89.78 - $106.23 $2.75 Million - $3.25 Million	-30,607 Reduced 87.39%	4,417 $409,000
Q4 2017 Jan 30, 2018	BUY	$89.56 - $98.21 $3.14 Million - $3.44 Million	35,024	35,024 $3.39 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.

Account